Other News To Note
Tuesday, July 26, 2011
NanoViricides Inc., of West Haven, Conn., said that its HIV candidate had equivalent efficacy to a highly active antiretroviral therapy triple drug cocktail in an animal study with no evidence of toxicity. The drug is designed to mimic the cellular structures that HIV uses to bind to cells, and has the potential to complement HAART therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.